The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elı́as Campo(Centro de Investigación Biomédica en Red de Cáncer), Elaine S. Jaffe(National Cancer Institute), James R. Cook(Cleveland Clinic), Leticia Quintanilla‐Martínez(University of Tübingen), Steven H. Swerdlow(University of Pittsburgh), Kenneth C. Anderson(Dana-Farber Cancer Institute), Pierre Brousset(Institut universitaire du cancer de Toulouse Oncopole), Lorenzo Cerroni(Medical University of Graz), Laurence de Leval(University of Lausanne), Stefan Dirnhofer(University of Basel), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Andrew L. Feldman(Mayo Clinic in Arizona), Falko Fend(University of Tübingen), Jonathan W. Friedberg(University of Rochester), Philippe Gaulard(Inserm), Paolo Ghia(Vita-Salute San Raffaele University), Steven M. Horwitz(Memorial Sloan Kettering Cancer Center), Rebecca L. King(Mayo Clinic in Arizona), Gilles Salles(Memorial Sloan Kettering Cancer Center), Jesús F. San Miguel(Navarre Institute of Health Research), John F. Seymour(The Royal Melbourne Hospital), Steven P. Treon(Dana-Farber Cancer Institute), Julie M. Vose(University of Nebraska Medical Center), Emanuele Zucca(Ente Ospedaliero Cantonale), Ranjana H. Advani(Stanford Blood Center), Stephen M. Ansell(Mayo Clinic), Wing-Yan Au, Carlos Barrionuevo(National University of San Marcos), Leif Bergsagel(WinnMed), Wing C. Chan(City Of Hope National Medical Center), Jeffrey I. Cohen(National Institutes of Health), Francesco d’Amore(Aarhus University Hospital), Andrew Davies(Cancer Research UK), Brunangelo Falini(University of Perugia), Irene M. Ghobrial(Harvard University), John R. Goodlad(National Health Service), John G. Gribben(Queen Mary University of London), Eric D. Hsi(Wake Forest University), Brad S. Kahl(Washington University in St. Louis), Won-Seog Kim(Samsung Medical Center), Shaji Kumar(Mayo Clinic), Ann S. LaCasce(Dana-Farber Cancer Institute), Camille Laurent(Institut universitaire du cancer de Toulouse Oncopole), Georg Lenz(University Hospital Münster), John P. Leonard(Cornell University), Michael P. Link(Stanford University), Armando López‐Guillermo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María‐Victoria Mateos(Universidad de Salamanca), Elizabeth Macintyre(Hôpital Necker-Enfants Malades), Ari Melnick(Cornell University), Franck Morschhauser(Centre Hospitalier Universitaire de Lille), Shigeo Nakamura(Nagoya University Hospital), Marina Narbaitz(Academia Nacional de Medicina), Astrid Pavlovsky, Stefano Pileri(European Institute of Oncology), Miguel Á. Piris(Universidad Autónoma de Madrid), Barbara Pro(Northwestern University), S. Vincent Rajkumar(Mayo Clinic in Arizona), Steven T. Rosen(City Of Hope National Medical Center), Birgitta Sander(Karolinska Institutet), Laurie H. Sehn(BC Cancer Agency), Margaret A. Shipp(Dana-Farber Cancer Institute), Sonali M. Smith(University of Chicago), Louis M. Staudt(National Institutes of Health), Catherine Thieblemont(Délégation Paris 7), Thomas Tousseyn(Universitair Ziekenhuis Leuven), Wyndham H. Wilson(National Institutes of Health), Tadashi Yoshino(Okayama University), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Martin Dreyling(Ludwig-Maximilians-Universität München), David W. Scott(BC Cancer Agency), Jane N. Winter(Northwestern University), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center)
Blood
June 2, 2022
Cited by 1,473Open Access
Full Text

Abstract

Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal. We have followed the same process that was successfully used for the third and fourth editions of the World Health Organization Classification of Hematologic Neoplasms. The definition, recommended studies, and criteria for the diagnosis of many entities have been extensively refined. Some categories considered provisional have now been upgraded to definite entities. Terminology for some diseases has been revised to adapt nomenclature to the current knowledge of their biology, but these modifications have been restricted to well-justified situations. Major findings from recent genomic studies have impacted the conceptual framework and diagnostic criteria for many disease entities. These changes will have an impact on optimal clinical management. The conclusions of this work are summarized in this report as the proposed International Consensus Classification of mature lymphoid, histiocytic, and dendritic cell tumors.


Related Papers

No related papers found

Powered by citation graph analysis